Sabby Management’s Gyre Therapeutics GYRE Stock Holding History

Sabby Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-114	Closed	-$350K	–	193
2021 Q3	$350K	Buy	+114	New	+$3.75K	0.05%	127
2014 Q1	–	Sell	-1	Closed	-$187K	–	253
2013 Q4	$187K	Buy	+1	New	+$3.94K	0.01%	185
2013 Q3	–	Sell	-1	Closed	-$352K	–	207
2013 Q2	$352K	Buy	+1	New	+$3.81K	0.02%	153

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Sabby Management's GYRE Position: Q2 2022 in Review

Sabby Management sold out of Gyre Therapeutics (GYRE) in Q2 2022, closing a stake of 176,000 shares — an estimated $871K sold.

Sabby Management first reported a position in GYRE in Q4 2013 and held it in 4 quarters. The position peaked at $1.04M in Q4 2021. 41 funds tracked by Wall St. Rank hold GYRE as of Q2 2022.

Sabby Management reported no remaining Gyre Therapeutics position as of Q2 2022 after selling out during the quarter.
Sabby Management sold 176,000 Gyre Therapeutics shares in Q2 2022, an estimated $871K.
Sabby Management first reported a position in Gyre Therapeutics in Q4 2013 and held it in 4 quarters.
Sabby Management's Gyre Therapeutics position peaked at $1.04M in Q4 2021.
41 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2022.

Based on Sabby Management's 13F filing for Q2 2022, filed 15 Aug 2022.